bpc-157 10mg reconstitution calculator Peptide | Solcara Health BPC-157 Tracker: Reconstitution, Dose Log

These treatments are relied upon by some of Californias most vulnerable populations, including chronic Lyme patients, people with cancer, and firefighters exposed to toxins on the job

A phase I safety study in healthy adults confirmed that subcutaneous MOTS-c injections at doses up to 10 mg produced no serious adverse events, with a pharmacokinetic profile supporting once-daily or every-other-day dosing [3]

Lack of FDA Approval and Regulation One of the most pressing issues with BPC-157 is its lack of approval by the Food and Drug Administration (FDA)

The nightly growth hormone pulse happens during slow-wave sleep

short 2.5 mg cohort about -4.7% at ~4 weeks, -12.7% by the 5 mg phase (Barrea 2026): Mody Diabetes Ther 2025